Neurovia Bioelectronics develops a reversible, minimally-invasive stent designed to target autonomic dysfunctions in patients with hypertension, particularly those aged 70 and above. This technology aims to improve blood pressure management and enhance health outcomes, potentially saving 20,000 lives annually.
Funding
$58.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hypertension management, especially in patients aged 70 and above, often requires invasive procedures and may not effectively target the underlying autonomic dysfunctions contributing to the condition. Current treatment options may not adequately address the needs of this specific demographic, leading to suboptimal health outcomes.
Solution
Neurovia Bioelectronics is developing a minimally-invasive, reversible stent designed to address autonomic dysfunctions in hypertension patients. The stent aims to improve blood pressure management by directly targeting the physiological mechanisms contributing to hypertension. This approach offers a less invasive alternative with the potential to enhance health outcomes and quality of life, particularly for older patients where traditional treatments may be less effective or carry higher risks. The technology is being developed as an innovative solution to fill a crucial gap in current hypertension treatment options.
Target Audience
The primary target audience includes hypertension patients, particularly those aged 70 and above, as well as healthcare providers specializing in cardiology and geriatric medicine.
Features
- Minimally-invasive stent design for ease of implantation and reduced patient trauma
- Reversible mechanism allowing for removal or adjustment as needed
- Targeted approach to address autonomic dysfunctions related to hypertension
- Focus on improving blood pressure management in patients aged 70 and above